At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 27, 2026 at 06:31 ET
Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, including up to $800 million in synthetic royalty funding and up to $500 million in senior corporate debt. Combined with its existing $1.3 billion cash, this positions Apogee to fund Phase 3 development and potential commercialization of zumilokibart without future equity financing. The deal is the largest royalty financing for a pre-Phase 3 program and was announced alongside APEX Phase 2 Part B data.
- Up to $1.3 billion in non-dilutive capital from Blackstone Life Sciences, including up to $800 million synthetic royalty and up to $500 million senior corporate debt.
- First $400 million preapproval funding: $100M at signing, $100M upon Phase 3 enrollment completion, $200M upon positive Phase 3 data.
- Up to $400 million additional funding available upon FDA approval, $150M at Apogee's option.
- Royalty term of 15 years on worldwide annual sales of zumilokibart, with no royalties on global annual sales exceeding $8 billion.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access